-2-

7346222928

5117-C1-01-MG

Amendments to the Claims:

This listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-75 (cancelled).

(Previously added): A compound having the structure and meanings for R as indicated:

wherein R is selected from the group consisting of:

- a) 4-BrPh;
- b) 4-COOEt-Ph;
- C) $4-CF_3Ph;$
- d) 3-Me-Ph;
- e) 3-COOEt-Ph;
- 3-COOtBu-Ph; f)
- g) 3-COOH-Ph;
- h) 4-MeO-Ph;
- i) 3-MeO-Ph; and
- j) 2-MeO-Ph.
- (Previously added): A compound selected from: Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-; Benzoic acid. 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy) phenyl] -4-oxo-2-quinazolinyl] hydrazino] carbonyl] amino] ethyl ester;

-3-

5117-C1-01-MG

F-716

Hydrazinecarboxamide. 2-[3,4-dihydro-3-[3-(1-methylethoxy) phenyl] -4-oxo-2-quinazolinyl] -N-(4-methoxyphenyl) -; Hydrazinecarboxamide. 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methoxyphenyl)-; Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy) phenyl] -4-oxo-2-quinazolinyl] -N-(2-methoxyphenyl) -; Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[(4-trifluoromethyl) phenyl] -; Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, 1,1-dimethylethyl ester; Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy) phenyl] -4-oxo-2-quinazolinyl] -N-(3-methylphenyl) -; Benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methy]ethoxy) phenyl] -4-oxo-2-quinazolinyl] hydrazino] carbonyl] amino] ethyl ester; Benzoic 2-[[[2-[3,4-dihydro-3-[3-(1-methylacid. ethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester;

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methyl-ethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-; and

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methyl-ethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]1,1-dimethylethyl ester.

78 to 79 (Cancelled).

80. (Previously added): A method of reducing gastric acid secretion in a mammal comprising administering an effective gastric acid secretion reducing amount to a mammal in need thereof a compound of Formula I:

-4-

5117-C1-01-MG

Formula

I

wherein W, X, Y, and

Z are C-R₃, C-R₄, C-R₅, and C-R₆; R_3 -R₆ are hydrogen; M is oxygen; A is O

-NH-C-NH; and

 R_1 and R_2 are substituted phenyl, wherein

the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂)_iOR₁₃
- $(CH_2)_{i}SR_{13}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix} - COOR_{13}$$

-5-

5117-C1-01-MG

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} - CONR_{13}R_{16}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} - NR_{13}R_{14}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{18} \end{pmatrix}_{i} = CONHSO_{2}R_{13}$$

 $(CH_2)_iO$ C(O) R_{I3}

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{13} \end{pmatrix}_{I} = S(O)_{j} R_{13}$$

and

-6-

7346222928

5117-C1-01-MG

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix} = S(O)_{j} N R_{13} R_{14} T_{14}$$

wherein i and j are independently 0, 1, 2,

 R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and

NR₁₃R₁₄ is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

81. (Previously added): A method of reducing anxiety in a mammal, comprising administering an effective anxiety reducing amount to a mammal in need thereof a compound of Formula I:

Formula

wherein W, X, Y, and Z are $C-R_3$, $C-R_4$, $C-R_5$, and $C-R_6$;

R₃-R₆ are hydrogen;

M is oxygen;

A is

-NH-C-NH; and

 R_1 and R_2 are substituted phenyl, wherein

the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂) iOR₁₃

-7-

PATENT PFIZER ANN ARBOR MI

5117-C1-01-MG

- (CH₂) iSR₁₃
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

$$\begin{pmatrix} R_{IS} \\ | \\ -C - \\ | \\ R_{IS} \end{pmatrix}_{i} - COOR_{IS}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} - CONR_{13}R_{14}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C - \\ | \\ R_{15} \end{pmatrix} = NR_{13}R_{14}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix} - CONHSO_2 R_{13}$$

-8-

5117-C1-01-MG

$$\begin{pmatrix} R_{16} \\ | \\ -C - \\ | \\ R_{15} \end{pmatrix}_{i} = S(O)_{j} R_{13}$$

and

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix} = S(O)_{j} N R_{15} R_{14} 14$$

wherein i and j are independently 0, 1, 2, R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and

 $NR_{13}R_{14}$ is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

82. (Previously added): A method for treating gastrointestinal ulcers in a mammal comprising administering an effective gastrointestinal ulcer treating amount to a mammal in need thereof a compound of Formula I:

Formula

I

wherein W, X, Y, and Z are $C-R_3$, $C-R_4$, $C-R_5$, and $C-R_6$;

-9-

5117-C1-01-MG

R₃-R₆ are hydrogen;

M is oxygen;

A is O

-NH-C-NH; and

 $\ensuremath{\text{R}}_1$ and $\ensuremath{\text{R}}_2$ are substituted phenyl, wherein

the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂) iOR₁₃
- (CH₂)₁SR₁₃
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix} - COOR_{13}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{l} - CONR_{13}R_{16}$$

-10-

5117-C1-01-MG

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} - NR_{15}R_{15}$$

From-

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{t} = CONHSO_{2} R_{13}$$

 $(CH_2)_i O C(O) R_{13}$

$$\begin{pmatrix} R_{I6} \\ | \\ -C \\ | \\ R_{I5} \end{pmatrix} - S(O)_{j} R_{I3}$$

and

$$\begin{pmatrix} R_{16} \\ | \\ -C - \\ | \\ R_{15} \end{pmatrix}_{i} = S(O)_{j} N R_{13} R_{14} 21$$

wherein i and j are independently 0, 1, 2, R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and

 $NR_{13}R_{14}$ is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

-11-

5117-C1-01-MG

83. (Previously added): A method of treating psychosis in a mammal comprising administering an effective psychosis in a mammal comprising administering an effective psychosis treating amount to a mammal in need thereof a compound of Formula I:

Formula

I

wherein W, X, Y, and Z are $C-R_3$, $C-R_4$, $C-R_5$, and $C-R_6$; R_3-R_6 are hydrogen;

M is oxygen;

A is

I

-NH-C-NH; and

 R_1 and R_2 are substituted phenyl, wherein

the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂) iOR₁₃
- (CH₂) iSR₁₃
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

-12-

5117-C1-01-MG

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{I} - COOR_{13}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} - CONR_{13}R_{16}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} - NR_{13}R_{14}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} -CONHSO_{2}R_{13}$$

 $(CH_2)_i O C(O) R_{i3}$

$$\begin{pmatrix} R_{16} \\ | \\ -C - \\ | \\ R_{15} \end{pmatrix} = S(O)_{j} R_{13}$$

-13-

5117-C1-01-MG

and

$$\begin{pmatrix} R_{16} \\ | \\ -C_{-} \\ | \\ R_{15} \end{pmatrix}_{i} = S(O)_{j} N R_{13} R_{14} 28$$

wherein i and j are independently 0, 1, 2,

 R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and

 $NR_{13}R_{14}$ is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

84 (Cancelled) .

85. (Previously added): A method of treating pain in a mammal comprising administering an effective amount to a mammal in need thereof a compound of Formula I:

Formula

I

wherein wherein

W, X, Y, and Z are $C-R_3$, $C-R_4$, $C-R_5$, and $C-R_6$;

R₃-R₆ are hydrogen;

M is oxygen;

A is

-NH-C-NH; and

 R_1 and R_2 are substituted phenyl, wherein

-14-

5117-C1-01-MG

the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂) iOR₁₃
- (CH₂) iSR₁₃
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{I} - COOR_{13}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} = CONR_{15}R_{14}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} = NR_{13}R_{14}$$

-15-

5117-C1-01-MG

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} = CONHSO_{2}R_{13}$$

 $(CH_2)_{i}O C(O) R_{i3}$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix} = S(O)_j R_{13}$$

and

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix} = S(O)_{j} N R_{13} R_{14} 35$$

wherein i and j are independently 0, 1, 2, R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and

 $NR_{13}R_{14}$ is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

86. (Previously added): A method of treating panic in a mammal comprising administering an effective amount to a mammal in need thereof a compound of Formula I:

-16-

5117-C1-01-MG

Formula

I

wherein W, X, Y,

and Z are $C-R_3$, $C-R_4$, $C-R_5$, and $C-R_6$;

R₃-R₆ are hydrogen;

M is oxygen;

A is

-NH-C-NH; and

 R_1 and R_2 are substituted phenyl, wherein

the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂) iOR₁₃
- (CH₂)₁SR₁₃
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

$$\begin{pmatrix} R_{16} \\ | \\ -C_{-} \\ | \\ R_{15} \end{pmatrix}_{i} - COOR_{13}$$

-17-

5117-C1-01-MG

$$\begin{pmatrix} R_{16} \\ | \\ -C - \\ | \\ R_{15} \end{pmatrix}_{i} - CONR_{13}R_{14}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C - \\ | \\ R_{15} \end{pmatrix}_{i} - NR_{13}R_{14}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C - \\ | \\ R_{15} \end{pmatrix}_{i} = CONHSO_{2} R_{13}$$

$$(CH_3)_i O C(O) R_{I3}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{l} = S(O)_{j} R_{13}$$

and

-18-

5117-C1-01-MG

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} = S(O)_{j} N R_{13} R_{14} 42$$

wherein i and j are independently 0, 1, 2,

 R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and

 $NR_{13}R_{14}$ is also mono or bicyclic ring with one to four hetero atoms as N.O.S.

87. (Previously added): A method of diagnosis of gastrindependent tumors in a mammal, comprising administering to the mammal in need thereof an effective diagnosing amount of a radiolabelled iodo compound of Formula I:

Formula

I

wherein W, X, Y,

and Z are $C-R_3$, $C-R_4$, $C-R_5$, and $C-R_6$;

R₃-R₆ are hydrogen;

M is oxygen;

Ais

-NH-C-NH; and

 R_1 and R_2 are substituted phenyl, wherein the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂)_iOR₁₃

-19-

5117-C1-01-MG

- (CH₂)_iSR₁₃
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

$$\left(\begin{array}{c} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{array} \right)_{I} = COOR_{13}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{l} = CONR_{13}R_{14}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C - \\ | \\ R_{15} \end{pmatrix}_{l} - NR_{13}R_{14}$$

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix}_{i} = CONHSO_{2}R_{13}$$

$$(CH_2)_i O C(O) R_{13}$$

-20-

5117-C1-01-MG

$$\begin{pmatrix}
R_{16} \\
| \\
-C \\
| \\
R_{15}
\end{pmatrix}_{j} = S(O)_{j} R_{13}$$

and

$$\begin{pmatrix} R_{16} \\ | \\ -C \\ | \\ R_{15} \end{pmatrix} = S(O)_{j} N R_{13} R_{14} 49$$

wherein i and j are independently 0, 1, 2, R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower alky, alkaryl of from 7 to 10 carbon atoms; and $NR_{13}R_{14}$ is also mono or bicyclic ring with one to four

87. (Cancelled).

hetero atoms as N,O,S.

- 88 (Cancelled).
- 89. (New): A pharmaceutically acceptable salt of the compound of claim 76.
- 90. (New): A pharmaceutically acceptable salt of the compound of claim 77.
- A pharmaceutical composition comprising the compound of claim 76 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

-21-

5117-C1-01-MG

92. (New): A pharmaceutical composition comprising the compound of claim 77 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier